A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common monogenetic disorders in humans and is characterized by numerous fluid-filled cysts that grow slowly, resulting in end-stage renal disease in the majority of patients. Preclinical studies have indicated that t...

Descripción completa

Detalles Bibliográficos
Autores principales: Blazer-Yost, Bonnie L, Bacallao, Robert L, Erickson, Bradley J, LaPradd, Michelle L, Edwards, Marie E, Sheth, Nehal, Swinney, Kim, Ponsler-Sipes, Kristen M, Moorthi, Ranjani N, Perkins, Susan M, Torres, Vicente E, Moe, Sharon M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243264/
https://www.ncbi.nlm.nih.gov/pubmed/34221381
http://dx.doi.org/10.1093/ckj/sfaa232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243264/
https://www.ncbi.nlm.nih.gov/pubmed/34221381
http://dx.doi.org/10.1093/ckj/sfaa232

Ejemplares similares